An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Vivani Medical plans to start a human trial in August of a new implant that slowly releases semaglutide, a drug used for diabetes and weight loss. The company recently struck a deal with Novo Nordisk, the maker of semaglutide drugs like Ozempic and Wegovy, which appears to clear a path for using the drug in Vivani’s device. The announcement is mainly about the trial timing and the partnership, not about finished results. Semaglutide is a medicine that acts like a natural hormone your gut makes after eating. That hormone tells your brain you’ve had enough to eat and slows how fast your stomach empties. Drugs with semaglutide are already sold as injections or higher-dose versions for weight loss under brand names such as Ozempic and Wegovy. An implant would aim to deliver the same drug steadily over a long time without daily or weekly shots. The news says Vivani will test the implant in people starting in August, which means this is an early-stage human trial — likely focused on safety and whether the device releases the drug predictably. The story does not report any trial results yet, or how many people will participate, or how well the implant works compared with existing injections. So at this point there’s no evidence that the implant improves outcomes; the announcement is about the start of testing and a business deal with Novo Nordisk. Why this matters is practical. Many people who use semaglutide drugs do so by injection, which some find inconvenient or uncomfortable. An implant that reliably delivers the drug could make treatment simpler and more consistent for people with diabetes or those using it for weight management. It could also change how often people visit clinics and how health systems handle these medications. Investors and patients watching the growing market for semaglutide-based treatments will care about new delivery options. There are important caveats. Early human trials mainly test safety and dosing, not long-term effectiveness. Implants can have device risks like infection, migration, or need for removal. The announcement doesn’t detail regulatory approval — a successful trial is only one step before wider availability. Also, the deal with Novo Nordisk likely covers supply or rights but doesn’t guarantee clinical success. People should not assume an implant will be available soon or be better than existing options until larger trials confirm that. Bottom line: Vivani is preparing to test a semaglutide-releasing implant in people after partnering with Novo Nordisk, but this is the start of testing and not evidence yet that the implant will be safe, effective, or widely available.
Source: Yahoo Finance